Financials
- Financial year
- 2025
- Total assets
- €11.1m
- Loss
- -€5.0m
- Solvency
- 81.5%
Total assets▼ 31.3%
Net result
20222025
Protealis
ActiveSummary
Protealis has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €9.1m and a net result of -€5.0m. Equity is growing by about 14% per year across the filed financial years. Its solvency ranks better than 79% of 271 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).
Overview
Activity
Research and development on biotechnology
NACE 72101Other research and development on natural sciences NACE 72109
2 sites
Size
≈ €1.9mturnover 2025, estimated
- Staff
- 17.2 FTE
- Equity
- €9.1m
- Loss
- -€5.0m
Turnover estimated from the gross margin
Structure
- Largest shareholder
- V-Bio Fund 2 · 11.9%
- Board
- 5 members
Auditor: Deloitte Bedrijfsrevisoren2025 accounts 56 days early9 of 17 deeds summarised
Why 84raises riskLoss of €5.0m, the second in a row (financial year 2025)lowers riskSector: Scientific research and development (NACE 72)Figures for financial year 2025 (filed 08-06-2026)Equity €9.1m (81.5% of total assets)Show the evidence
Checked score
Score 2025
84
/ 100
Excellent
Probability in this band: under 0.55%
Financially better than 44% of its sector peers (NACE 72, small)
Financial strength · tick = 2024
Average
Solvency
100=
equity 81.5% of total assets
Liquidity
64+9
short-term debt 8.3% · cash 11.3%
Profitability
0=
return on assets -44.8%
Bankruptcy probability, 12 months
0.4%
Very low
0%0.5%1.5%4%10%≥ 25%
About 4 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 0.1%lowest value
12-2024: 0.1%● unchanged vs 11-2024lowest value
01-2025: 0.1%● unchanged vs 12-2024lowest value
02-2025: 0.1%● unchanged vs 01-2025lowest value
03-2025: 0.1%● unchanged vs 02-2025lowest value
04-2025: 0.1%● unchanged vs 03-2025
05-2025: 0.1%● unchanged vs 04-2025
06-2025: 0.1%● unchanged vs 05-2025
07-2025: 0.4%▲ +0.3 percentage points vs 06-2025
08-2025: 0.4%● unchanged vs 07-2025
09-2025: 0.4%● unchanged vs 08-2025
10-2025: 0.4%● unchanged vs 09-2025
11-2025: 0.4%● unchanged vs 10-2025
12-2025: 0.4%● unchanged vs 11-2025
01-2026: 0.4%● unchanged vs 12-2025
02-2026: 0.4%● unchanged vs 01-2026
03-2026: 0.4%● unchanged vs 02-2026
04-2026: 0.4%● unchanged vs 03-2026
05-2026: 0.4%● unchanged vs 04-2026
06-2026: 0.5%▲ +0.1 percentage points vs 05-2026highest value
07-2026: 0.3%▼ -0.2 percentage points vs 06-2026
08-2026: 0.3%● unchanged vs 07-2026
09-2026: 0.3%● unchanged vs 08-2026
10-2026: 0.4%▲ +0.1 percentage points vs 09-2026
Credit of up to €750,000 on 30-day terms is acceptable
Liquidity ample (current ratio 11.05, compared with 20.96 in 2024, above the usual 1.5; short-term debt: 8.3% and cash: 11.3% of total assets), and 18.5% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, small): better than 85% on solvency, 64% on liquidity, 11% on profitability and 15% on growth.
The bankruptcy probability was computed on 29-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025Net result per financial year
22232425
2022 to 2025 · latest year -€5.0m
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 05-06-2026, 56 days ahead of the deadline.
NBB · 4 filingsDeviation from the deadline
2025
56 days early
2024
65 days early
2023
63 days early
2022
81 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 4 accounts on average 66 days before the deadline; the sector median (NACE 72) for financial year 2024 is 13 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 29 May (4 of the last 4 filed years within 30 days of that day).
Companies Code · seven monthsWhere today falls in the filing period
30-10-2026 today31-12-2026 year end31-07-2027 deadline
- Annual accounts filedfinancial year 2025 · abbreviated…
- Capital & shares · Amendment of…Capital decrease · Capital
- Resignation: Johan Cardoen (director)Appointment: Tom Viaene (oprichtende entiteit…
Key points
- Risk: 4 loss-making years in a rowloss financial year 2025 -€5.0m View
- Caution: Among the weakest 5% on net resultsector median €1,640 · 270 companies -€5.0m View
- Flemish supportawarded from 2022 to 2025 €2.7m View
- Caution: Equity fell in 2025from €14.0m to €9.1m ▼ 35.5% View
- Board changedlatest change 01-04-2026 · 5 in office 1 joined · 1 left View
- Positive: Always filed on timeaccounts within the deadline every year 4 years View
By topic
Board & ownership
- Board
- 5 members
- Largest shareholder
- V-Bio Fund 2 · 11.9%
- Auditor
- Deloitte Bedrijfsrevisoren
- KORYS MANAGEMENTDirector
- Hartmut van LengerichDirector
- VAN LIERDE François JulesDirector
- DE LIER BVDirector
- Tom ViaeneDirector
Network & group
- Connected companies
- 20
Timeline
- Events
- 16
- Since
- 2023
- Next accounts
- by 31-07-2027
- 31-12-2025Weakest financial year
- 30-05-2025Reappointment: Deloitte Bedrijfsrevisoren (statutory auditor)
- 27-05-2025Annual accounts filed
Company details
- Sites
- 2
- Legal form
- Public limited company
- Activity
- Research and development on biotechnologyNACE 72101
- Founded
- 16-03-2021
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Articles of association
- Provisions read
- 25
- Annual meeting
- First Wednesday of May at 10:00
Key facts about Protealis
- What is the company number of Protealis?
- 0765.251.410. In Belgium the VAT number is the company number with BE in front: BE 0765.251.410.
- Where is Protealis based?
- The registered office is at Technologiepark-Zwijnaarde 94, 9052 Gent.Company details
- What does Protealis do?
- According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
- What is the legal form of Protealis?
- Public limited company (NV).
- When was Protealis founded?
- On 16-03-2021.
- Is Protealis still active?
- Yes, Protealis is an active enterprise in the KBO register.
- How many employees does Protealis have?
- On average 17.2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of Protealis?
- Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.
- Is Protealis profitable?
- In financial year 2025, Protealis made a loss of €5.0m.
- Where can I find the annual accounts of Protealis?
- Protealis filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Protealis due?
- By 31-07-2027, for financial year 2026.Timeline
Companies related to Protealis
Shareholders
- V-Bio Fund 211.9%
- Agri Investment Fund11.88%
- KORYS INVESTMENTS11.5%
- AMPHIBEAN0.23%
Comparable companies
- BIOMEDICAL SYSTEMSLeuven
- EPICS THERAPEUTICSCharleroi
- Swedish Orphan Biovitrum (Belgium)Zaventem
- DIAGENODESeraing
- Intrexon ActobioticsNazareth-De Pinte
Go further with this company
How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Is the workforce growing, and do people stay?Employer check Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What support did similar companies receive that this one did not?Subsidies
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.